TodayBuildContextBrowseMore
stackBETAv0.1
TodayBuild a stackCommon stacksEncyclopediaPulse
Methodology
← Back to your stack
Monograph
RESEARCH GREYS-002
Hormones

Fadogia Agrestis

West African shrub extract. Proposed LH-mimetic mechanism increasing testicular testosterone production via luteinizing hormone pathway sensitization — though human trial data is sparse.

ExperimentalHormones
Typical dose400–600 mg/day (typical community dose; no established human clinical dose)
Frequencydaily, oral
Half-life6h
Citations indexed4
DeliveryOral
Half-life~6h
EvidenceExperimental
Citations4
Similar compounds
Synergy checkCompare
Research grey

This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.

Mechanism

Popularized by Andrew Huberman. Primary human evidence is essentially nil — testosterone-boosting claims rest on a 2005 rat study (Yakubu et al.) using doses scaling to ~1,200 mg/day in humans. The same rat studies showed dose-dependent testicular toxicity at higher doses, suggesting a narrow therapeutic index in rodents. Until well-powered human RCTs exist, Stack grades testosterone-boosting claims as experimental and the testicular toxicity signal as a real concern at high doses.

Specifics
Low energy / fatigue
Caveats

Testicular toxicity signal in rat studies at high doses — do NOT exceed established community doses. Monitor labs (testosterone, LH, FSH) if running >8 weeks. Human efficacy data is essentially absent — you are extrapolating from rodents.

Evidence levelExperimental
Regulatory statusNot FDA-reviewed for efficacy. Sold as dietary supplement under DSHEA. No prohibited status under WADA.
DNA / pharmacogenomicsLow — No known pharmacogenomic interactions. Androgen receptor sensitivity variants (AR CAG repeats) may modulate response.
References

External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.

  • PubMedEN
    MECHANISTICAcademic-fundedVerified today
    Yakubu MT et al. — Fadogia agrestis rat study (Asian J Andrology 2005)
RESEARCH GREYS-002

Not FDA-reviewed for efficacy. Sold as dietary supplement under DSHEA. No prohibited status under WADA.

Can I get it? →
Field reports

Distilled themes from named communities — Reddit threads, forums, creator commentary. Not direct quotes; not clinical evidence. Useful for calibrating expectations against what real self-experimenters report.

r/Testosterone + Huberman Lab community

High adoption post-Huberman podcast mention. Community reports subjective libido/energy improvement at 400 mg. No controlled comparison data to separate placebo. Cycling 8 weeks on / 4 weeks off is the common harm-reduction protocol.

Fadogia400–600 mg/day (typical community dose; no established human clinical dose) · daily, oral
Discussion guide, not prescription

stack is an exploration engine. Output is a discussion guide for a conversation with a licensed provider — never a prescription, dose recommendation, or sourcing instruction. Peptides discussed include compounds with limited human evidence and varying legal status by jurisdiction. Verify everything with a qualified clinician before any decision.

Full terms →
stackv0.1
AudiencesWho Stack is forFor researchersFor pharmaciesFor cliniciansFor press
Trust & regulatoryCalibrationMethodologyFDA statusPharmacy registryPCAC commentMX · COFEPRIS
Built honest. Bilingual from day one.